Spex Capital launches €100m fund to back early-stage healthtech ventures globally.
The newly launched vehicle aims to accelerate technology adoption in healthcare through seed and Series A investments.
Spex Capital is a digital health and med-tech investment management firm that backs early-stage ventures. The firm works to advance breakthrough healthcare systems globally.
Spex Capital has launched a global healthtech fund with a target size of €100m to back early-stage ventures. The vehicle is established as a designated Article 9 impact fund and will write tickets up to €5m for seed and Series A companies. The launch is supported by an exclusive partnership with MedCity and senior appointments including Mount Sinai Ventures.
From the founder
"Even before Covid-19, the drive for countries to make better use of digital technology in healthcare had already begun. With this fund, our partnership with MedCity, and a broad network of high calibre Senior Advisors, we will have unparalleled access to invest in the best startups within this space."
Claudio D’Angelo
Founder and CEO at Spex Capital
Investor perspective
"I’m excited to take part in the launch of the Spex Venture HealthTech Fund at a time of radical change for the healthtech sector. History has shown us time and time again that economic downturns provide an impetus for innovation and that some of the strongest vintages have come from recession years. We now have an opportunity to acquire high quality assets at discounted valuations. We look forward to shaping the global healthcare ecosystem by helping innovators in developing ground-breaking technologies and solutions to overcome healthcare challenges worldwide."
Brent Stackhouse
Senior Partner, Mount Sinai Ventures
Categories
About the company
Spex Capital
Spex Capital invests in digital health and med-tech solutions to address global healthcare challenges.